Anti-premature leukemia protein (PML) was first identified in patients with acute promyelocytic leukemia, and this protein can participate in the regulation of a variety of biological processes such as apoptosis, senescence, and DNA repair, as well as being an important oncogenic protein. As a tumor suppressor, the expression of PML protein is significantly down-regulated in a variety of tumors, indicating that it is closely related to tumor formation. Its expression is not only limited to hematological tumors, but also plays a role in the genesis and development of solid tumors such as prostate cancer, lung cancer and melanoma. PML proteins showed down-regulated expression or gene deletion in a variety of malignant tumors, suggesting that PML proteins play an important role in the development of malignant tumors. Further studies have found that PML proteins can play an anti-tumor role by inhibiting cell proliferation, cell migration, and angiogenesis of tumor cells. For specific knowledge, consult a hematologist.